May 29, 2020 / 5:07 AM / a month ago

BRIEF-Roche: Updated Data On Roche's Alecensa

May 29 (Reuters) - Roche Holding AG:

* UPDATED DATA DEMONSTRATE ROCHE’S ALECENSA INCREASES OVERALL SURVIVAL RATE FOR PEOPLE WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER

* ALEX STUDY IS FIRST GLOBAL PHASE III STUDY TO SHOW A CLINICALLY MEANINGFUL BENEFIT IN OVERALL SURVIVAL AT FIVE YEARS (62.5% WITH ALECENSA), COMPARED WITH CRIZOTINIB (45.5%)

* DATA CONFIRM LONGER-TERM EFFICACY OF ALECENSA, BOTH IN PATIENTS WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES AT BASELINE

* DATA FURTHER SUPPORT ALECENSA AS STANDARD OF CARE FOR PEOPLE WITH METASTATIC ALK-POSITIVE NSCLC Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below